Navigation Links
Plato BioPharma, Inc. Sponsors Novel Disease Model Award
Date:4/1/2011

WESTMINSTER, Colo., April 1, 2011 /PRNewswire/ -- Plato BioPharma, Inc. ("PBI") announced today that the company has committed to sponsor The American Physiological Society's (APS) Novel Disease Model Awards for 2011 through 2013.  Each year, the APS's Physiologists in Industry Committee selects a Predoctoral and Postdoctoral fellow at the Experimental Biology conference as award recipients based on competitive abstract submissions.

"PBI embraces sponsorship of these awards to recognize outstanding trainees participating in, and driving toward approaches to study physiological mechanisms and consequences of diseases in integrative and mechanistically novel systems," said Craig F. Plato, Ph.D., CEO and founder of PBI.  "Additionally, as PBI is a preclinical contract research organization emphasizing physiological readouts in its assessment of disease models, as well as novel and integrative approaches to evaluate potential new therapeutic approaches to modify pathophysiological derangements, the Novel Disease Model Awards are squarely aligned with our scientific and business focus.  Thus, PBI truly appreciates the impact of recognizing young and talented investigators making contributions to the study and development of preclinical models of disease that may yield new avenues in the process of drug discovery."

This year's awards will be announced at the Experimental Biology conference, which is scheduled for April 9-13, 2011 in Washington, D.C.  Craig F. Platoof, PBI, and Martin Frank, Ph.D., Executive Director of The APS, will present the Novel Disease Model awards to the recipients at the APS Business Meeting.

Founded in 2009, Plato BioPharma, Inc. is a leading preclinical contract research organization (CRO).  The company offers expert drug discovery and development capabilities in cardiovascular, renal, pulmonary, and hepatic disease therapeutic areas.  PBI provides an integrated research platform from the in-life phase through clinical chemistry, biomarker and histological analyses.  The company specializes in custom study design and execution engagements ranging from pharmacokinetics through disease model and proof-of-concept evaluation.  PBI is headquartered in Westminster, Colorado.

CONTACT: Bob Leahy, +1-303-506-6960, for Plato BioPharma, Inc.


'/>"/>
SOURCE Plato BioPharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ticagrelor Reduced Cardiovascular Deaths and Heart Attacks in ACS Patients Undergoing Heart Procedures: New Data from PLATO Trial
2. New PLATO Sub-Analysis of CABG Patients Presented at ACC
3. Plato BioPharma, Inc Appoints New Board Member
4. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
5. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
6. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
7. Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug
8. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Receives New Research Grant From Hong Kong Innovation and Technology Commission
9. Enox Biopharma, Inc. to Present at OneMedForum Emerging Company Finance Conference.
10. Enox Biopharma, Inc. to Present at IN3 West Investment in Innovation Conference.
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 24, 2016 According to a ... (Standard Pen Needles, Safety Pen Needles), Needle Length (4mm, ... Hormone), Mode of Purchase (Retail, Non-Retail) - Trends & ... studies the market for the forecast period of 2016 ... 2.81 Billion by 2021 from USD 1.65 Billion in ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 23, 2016 Any dentist who has made an ... current process. Many of them do not even offer this ... and high laboratory costs involved. And those who ARE able ... such a high cost that the majority of today,s patients ... Parsa Zadeh , founder of Dental Evolutions Inc. and ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, ... treatment. Dr. Cheng has extensive experience with all areas of orthodontics, including robotic ... osteogenic orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative ... has initiated cultivation and processing operations at its production facility, and opened its ... Puradigm is the manufacturer of a complete system of proactive air and surface ...
Breaking Medicine News(10 mins):